News & Updates

CKD management in primary care: Why use SGLT2i?
CKD management in primary care: Why use SGLT2i?
25 Feb 2025 byDr. Catherine Xiao-Rui Chen, Department of Family Medicine and Primary Healthcare, Kowloon Central Cluster, Hospital Authority; Prof. Per-Henrik Groop, University of Helsinki, Finland; Dr. Maggie Ma, Combined Renal Replacement Services, Queen Mary Hospital; Dr. Ting-Bong Chan, Jockey Club School of Public Health and Primary Care, Chinese University of Hong Kong

Primary care physicians, as patients’ first point of contact, play an important role in early detection and timely management of chronic kidney disease (CKD). Sodium-glucose cotransporter-2 inhibitors’ (SGLT2i) positive data in CKD trials have established their role as first-line therapy recommended by international and Hong Kong guidelines. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts reviewed empagliflozin’s benefits in broad populations of CKD patients, and discussed how its early initiation may slow CKD progression and delay dialysis. Case reports were presented to illustrate real-world benefits of empagliflozin among patients managed in primary care in Hong Kong.

CKD management in primary care: Why use SGLT2i?
25 Feb 2025
Experts look beyond BMI to diagnose obesity
Experts look beyond BMI to diagnose obesity
24 Feb 2025 byElvira Manzano

Experts have proposed a subtle approach to diagnosing obesity that shifts the focus from BMI alone. Instead, they urged using other body fat measures such as waist circumference or direct fat mass measurement and signs and symptoms of ill health to confirm excess body fat.

Experts look beyond BMI to diagnose obesity
24 Feb 2025
Greater weight loss at 5 years following ring-augmented RYGB
Greater weight loss at 5 years following ring-augmented RYGB
22 Feb 2025 byMike Ng

Among patients who undergo primary RYGB to treat obesity, those whose surgery is augmented with a prefabricated gastric ring lose significantly more of their initial weight at 5 years, a matched cohort study has found

Greater weight loss at 5 years following ring-augmented RYGB
22 Feb 2025
Breastfeeding protects women against postpartum CVD
Breastfeeding protects women against postpartum CVD
20 Feb 2025 byStephen Padilla

Women who breastfeed, especially those with prior gestational diabetes mellitus (GDM), appear to have greater protection against long-term atherosclerotic cardiovascular disease (ASCVD), suggest the results of a study presented at SMFM 2025.

Breastfeeding protects women against postpartum CVD
20 Feb 2025